topline

SINGAPORE (April 5): CIMB Research is maintaining its “add” recommendation on Tianjin Zhongxin Pharmaceutical Group with an unchanged target price of US$1.30 ($1.82) as it continues to like the S-share as a “cheap proxy for China’s growing pharmac